BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease
Go back to BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease| (NASDAQ: BIVI) | Delayed: 2.09 +0.09 (4.50%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.00 | 52 Week High | $0.40 | |||
| Open | $2.06 | 52 Week Low | $0.17 | |||
| Day High | $2.20 | P/E | N/A | |||
| Day Low | $2.00 | EPS | $0.00 | |||
| Volume | 226,237 | |||||
